First, More Vectors. Then, More Genes
Executive Summary
This month's merger agreement between financially sound, but scientifically narrow Cell Genesys Inc. (Foster City, CA)and the troubled, but technology-rich Somatix Therapy Corp. (Alameda, CA) [See Deal] was played to the investment community as an ideal match-up-a play for critical mass in the complex and clinically demanding field of gene therapy. Although the merits of size may seem self-evident, we may still ask, why is bigger better?
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.